ProShare Advisors
HARP

ProShare Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

ProShare Advisors’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,070
Closed -$148K – 2336
2021
Q2 		$148K Buy
+1,070
New +$204K ﹤0.01% 2220

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's HARP Position: Q3 2021 in Review

ProShare Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2021, closing a stake of 1,070 shares — an estimated $148K sold.

ProShare Advisors first reported a position in HARP in Q2 2021 and held it in 1 quarter. The position peaked at $148K in Q2 2021. 93 funds tracked by Wall St. Rank hold HARP as of Q3 2021.

  • ProShare Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • ProShare Advisors sold 1,070 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $148K.
  • ProShare Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • ProShare Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $148K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on ProShare Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.